The two drugmakers' treatment was found to slow Alzheimer’s progression at its highest dose, allowing the partnership to move forward with late-stage clinical trialsOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.